Vectibix clinical trials (correction)
Amgen said it is continuing to study Vectibix (panitumumab), which failed to show survival benefits in a Phase IIIb trial, as a single biologic combined with chemotherapy in two Phase III trials in the first-and second-line of metastatic colorectal cancer. A previous article suggests that Vectibix failed to show survival benefits in a Phase IV commitment (1"The Pink Sheet" Aug. 20, 2007, p. 16). Phase IV commitments for Vectibix are progressing well, notably the registrational Phase III trial in the second-line of metastatic colorectal cancer, Amgen says...
You may also be interested in...
FDA is moving towards potentially withdrawing, for the first time, a drug brought to market under the Subpart H accelerated approval mechanism
Plan for rolling submission means US FDA filing of GIP/GLP1 agonist in obesity could be complete by April 2023, setting up possibility of late 2023 approval.
Companies will have more fragrance allergens to report to California health authorities if the European Union requires more than 50 additional fragrance allergens to be labeled on cosmetic products, as proposed by the Commission in September.